Targeted Therapy Against Bcl-2-Related Proteins in Breast Cancer Cells
Author Information
Author(s): Emi Manabu, Kim Ryungsa, Tanabe Kazuaki, Uchida Yoko, Toge Tetsuya
Primary Institution: Hiroshima University
Hypothesis
The study examines the relationship between the expression of Bcl-2 and Bcl-xL and the chemosensitivity of breast cancer cells to develop specific targeted therapy.
Conclusion
Targeted therapy against Bcl-2 protein using antisense oligodeoxynucleotides may enhance the effects of chemotherapy in breast cancer patients.
Supporting Evidence
- Treatment with antisense Bcl-2 and Bcl-xL ODNs resulted in a decrease in protein expression.
- AS Bcl-2 increased chemosensitivity to doxorubicin, mitomycin C, paclitaxel, and docetaxel.
- Transfection of the Bcl-2 gene into MDA-MB-453 cells decreased sensitivity to doxorubicin and mitomycin C.
- AS Bcl-xL increased chemosensitivity to doxorubicin and mitomycin C, but to a lesser extent than AS Bcl-2.
Takeaway
Scientists found that blocking certain proteins in breast cancer cells can make them more sensitive to chemotherapy, which could help treat the disease better.
Methodology
The study used four human breast cancer cell lines and tested the effects of antisense Bcl-2 and Bcl-xL phosphorothioate oligodeoxynucleotides on chemosensitivity in vitro and in vivo.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website